Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI).

Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR Jr, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI)†.

Front Aging Neurosci. 2013 Apr 1;5:11. doi: 10.3389/fnagi.2013.00011. eCollection 2013.

2.

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001. Review.

3.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
4.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

5.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Review.

6.

[Current topics about mild cognitive impairment (MCI)].

Yamamoto Y.

Seishin Shinkeigaku Zasshi. 2011;113(6):584-92. Review. Japanese.

PMID:
21815470
7.

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22. Review.

PMID:
28342697
8.

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, Munsie LM, Hu X, Soares HD, Potkin SG, Thompson PM, Kauwe JS, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):792-814. doi: 10.1016/j.jalz.2015.05.009. Review.

9.

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?

Ba M, Kong M, Li X, Ng KP, Rosa-Neto P, Gauthier S.

Transl Neurodegener. 2016 Nov 16;5:20. eCollection 2016. Review.

10.

Cognitive decline in Parkinson disease.

Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C.

Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. Review.

PMID:
28257128
11.

Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease.

Apter JT, Shastri K, Pizano K.

Curr Geriatr Rep. 2015;4(4):312-317. Epub 2015 Jul 30. Review.

12.

Buying time: a rationale for examining the use of circadian rhythm and sleep interventions to delay progression of mild cognitive impairment to Alzheimer's disease.

Landry GJ, Liu-Ambrose T.

Front Aging Neurosci. 2014 Dec 8;6:325. doi: 10.3389/fnagi.2014.00325. eCollection 2014. Review.

13.

Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids.

Fiala M, Kooij G, Wagner K, Hammock B, Pellegrini M.

FASEB J. 2017 Apr 18. pii: fj.201700065R. doi: 10.1096/fj.201700065R. [Epub ahead of print] Review.

PMID:
28420693
14.

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, Hartley D, Kawas C, Kremen S, Lingler J, Lopez OL, Mapstone M, Pierce A, Rabinovici G, Roberts JS, Sajjadi SA, Teng E, Karlawish J.

Alzheimers Res Ther. 2017 May 4;9(1):35. doi: 10.1186/s13195-017-0261-y. Review.

Supplemental Content

Support Center